Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 2, 2009, Pages 89-100

  Batlle, Javier ^a   López Fernández, María Fernanda ^a   Fraga, Esther Lourés ^a   Trillo, Angela Rodríguez ^a   Pérez Rodríguez, María Almudena ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Factor replacement; FVIII.C; High molecular weight multimers; Thromboprophylaxis; Von Willebrand disease; Von Willebrand factor; VWF:RCo

Indexed keywords

BIOSTATE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; EMOCLOT; FACTANE; FACTOR 8Y; FANHDI; GREENEIGHT; HAEMOSOLVATE FACTOR VIII; HEMORAAS SD PLUS H; INNOBRAND; KOATE P; LOW MOLECULAR WEIGHT HEPARIN; OCTANATE; OPTIVATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RISTOCETIN COFACTOR; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CONCENTRATE; WILATE; WILFACTIN;

ALLERGIC REACTION; BLEEDING; BLEEDING TIME; CLINICAL TRIAL; CRYOPRECIPITATION; DEEP VEIN THROMBOSIS; DISEASE CONTROL; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG PURITY; DRUG SAFETY; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MOLECULAR WEIGHT; MUCOSAL BLEEDING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VON WILLEBRAND DISEASE;

CLINICAL TRIALS AS TOPIC; DEAMINO ARGININE VASOPRESSIN; DRUG COMBINATIONS; FACTOR VIII; HEMOSTASIS; HEMOSTATICS; HUMANS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; THROMBOSIS; TIME FACTORS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 62349135194     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283254570     Document Type: Review

References (55)

1. Mannucci PM. Treatment of von Willebrand disease. N Engl J Med 2004; 351:683-694.
2. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Italian Association of Hemophilia Center (AICE). Haemophilia 2002; 8:607-621.
3. Batlle J, Noya MS, Giangrande P, Lopez-Fernandez MF. Advances in the therapy of von Willebrand disease. Haemophilia 2002; 8:301-307.
4. Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88:94-108.
5. Perkins HA. Correction of the hemostatic defects in von Willebrand disease. Blood 1967; 30:375-380.
6. Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14:171-232.
7. Booker M. Registry of clotting factor concentrates. 8th ed. World Federation of Haemophilia 2008. www.wfh.org.
8. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10:243-249.
9. Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA, Humate-P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrates (Humate-P). Haemophilia 2004; 10:42-51.
10. Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA, Humate-P Study Group. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003; 9:688-695.
11. Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, et al. Efficacy and safety of factor VIII/von Willebrand factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003; 88:1279-1283.
12. Meriane F, Zerhouni L, Djeha N, Meriane F, Zerhouni L, Djeha N. Biological effects of a S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease. Blood Coagul Fibrinolysis 1993; 4:1023-1029.
13. Berntorp E, Nilsson IM. Use of a high-purity factor VIII concentrate (Humate-P) in von Willebrand disease. Vox Sang 1989; 56:212-217.
14. Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR, et al. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb Haemost 1994; 71:173-179.
15. Kreuz W, Mentzer D, Becker S, Scharrer I, Kornhuber B. Haemate-P in children with von Willebrand disease. Haemostasia 1994; 24:304-310.
16. Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99:450-456.
17. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79:3130-3137.
18. Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand disease with a VHP VWF concentrate: the French experience. Haemophilia 1998; 4 (suppl 3):48-52.
19. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4 (suppl 3):33-39.
20. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87:224-230.
21. Mazurier C, De Romeuf C, Parquet-Gernez A, Goudemand M. In vitro and in vivo characterization of a high-purity, solvent/detergent treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand's disease. Eur J Haematol 1990; 75:228-233.
22. Pasi KJ, Williams MD, Enayat MS, Hill FGH. Clinical and laboratory evaluation of the treatment of von Willebrand disease patients with heat treated factor VIII concentrate (BPL 8Y). Br J Haematol 1990; 75:228-233.
23. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand disease type III. Ann Hematol 1992; 65:253-259.
24. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM, HAEMATE P Surgical Study Group. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5:1420-1430.
25. Favaloro EJ, Lillicrap D, Lazzari MA, Cattaneo M, Mazurier C, Woods A, el al. von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia 2004; 10 (suppl 4): 164-168.
26. Chang AC, Rick ME, Ross Pierce L, Weinstein MJ. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Haemophilia 1998; 4 (suppl 3):1-6.
27. Favaloro EJ, Bukuya M, Martinelli T, Tzouroutis J, Duncan E, Welldon K, et al. A comparative multilaboratory assessment of three factor VIII/von Willebrand factor concentrates. Thromb Haemost 2002; 87:466-476.
28. Mazurier C. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease. Semin Thromb Hemost 2006; 32:529-536.
29. Budde U, Metzner HJ, Müller HG. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost 2006; 32:626-635.
30. Mazurier C, Poulle M, Samor B, Hilbert L, Chtourou S. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 2004; 86:100-104.
31. Lopez-Fernandez MF, Lopez-Berges C, Corral M, Garcia-Talavera JR, Lopez Borrasca A, Batlle J. Assessment of multimeric structure and ristocetin-induced binding to platelets of von Willebrand factor present in cryoprecipitate and different factor VIII concentrates. Vox Sang 1987; 52:15-19.
32. Mannucci PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood 1994; 83:3018-3027.
33. Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, Muller HG, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 1998; 4 (suppl 3):25-32.
34. Batlle J, Noya MS, Perez-Rodriguez A, Lourés E, López Fernándz MF. Therapy of von Willebrand disease and its monitoring [In Spanish]. Haematologica (Spanish edition) 2004; 89 (suppl 1):10-19.
35. Morfini M, Mannucci PM, Tenconi PM, Longo G, Mazzucconi MG, Rodeghiero F, et al. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease. Thromb Haemost 1993; 70:270-272.
36. Menache D, Aronson DL. New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates. Thromb Haemost 1997; 78:566-570.
37. Lopez-Fernandez MF, Blanco-Lopez MJ, Castineira MP, Batlle J. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII. Am J Hematol 1992; 40:20-27.
38. Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multicentre study. Thromb Haemost 2007; 97:922-930.
39. Favaloro FJ, Kershaw G, McLachlan AJ, Lloyd J. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease. Semin Thromb Hemost 2007; 33:745-758.
40. Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007; 5:1115-1124.
41. Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII - von Willebrand factor concentrate (Haemate P). Blood Coagul Fibrinolysis 2004; 15:323-330.
42. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrand disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83:127-135.
43. Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91:1325-1331.
44. Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82:35-39.
45. van Vliet HH, Kappers-Klunne MC, Leebeek FW, Michiels JJ. PFA-100 monitoring of von Willebrand factor (VWF) responses to DDAVP and FVIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost 2008; 100:462-468.
46. Favaloro EJ. A better approach to monitoring of therapy in von Willebrand disease? Thromb Haemost 2008; 100:371-373.
47. Laub R, Di Giambattista M, Fondu P, Brackmann HH, Lenk H, Saenko EL, et al. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. Thromb Haemost 1999; 81:39-44.
48. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345:152-155.
49. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83:5-9.
50. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:457-462.
51. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88:378-379.
52. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88:387-388.
53. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ, Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004; 351:1081-1088.
54. Nowak-Gottl U, Kosch A. Factor VIII, D-dimer, and thromboembolism in children. N Engl J Med 2004; 351:1051-1053.
55. Cristina L, Benilde C, Michela C, Mirella F, Giuliana G, Gualtiero P. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004; 124:504-510.